Health ❯ Healthcare ❯ Research
Trial Results Phase 3 Trials Efficacy Studies Trial Outcomes AI in Medicine Gene Therapy Trials Cancer Research Trial Methodology Animal Studies Pediatric COVID-19 Studies Human Trials Neurodegenerative Diseases Exercise and Cancer Neuroscience ASH Annual Meeting Patient Advocacy Long-term Outcomes Pain Therapies Monoclonal Antibodies for Covid-19 KARDIA-2 Study Drug Development Drug Approval Process Innovation Strategies Collaboration in Medicine Outcomes Research Translational Pathology Genetic Research Alzheimer's Drug Trials Innovative Therapies FRONTIER2 Trial Biomarkers in Neurology Mass General Brigham University-Hospital Collaboration Patient Care Data Integration OHSU Genetic Counseling Disease Modification Pediatric NeuroRecovery Gastroenterology Rare Diseases Neurological Research GINECO Group Caries Detection Neuroscience Studies Phase 2 Trials Pediatric Research Gastroparesis Research Cardiovascular Clinical Research Innovation in Medicine Grant Funding Post-COVID-19 Research Literature Review Treatment Paradigms Rare Disease Research Cancer Immunotherapy Tick-Borne Diseases Phase 3 Studies Gene Therapy
The 13,631-square-foot facility consolidates therapy, research and training to speed treatment for children with spinal cord and other neurological injuries.
